

DAFTAR PUSTAKA

- Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P: Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. *FertilSteril*. 1997, 6: 917–22.
- Assisted Reproductive. Report of a meeting on “Medical, Ethical and Social Aspects of Assisted Reproduction” held at WHO Headquarters in Geneva, Switzerland. 2001:17–21.
- Barbieri RL, Hornstein MD: Assisted reproduction—in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin-releasing hormone analogues. *Endocr Rev*. 1999, 20:249–52.
- Bullent, Bulbul Y, Onvutral A, Yorukogiu K, Posaci C, Demir N. Accuracy of ovarian reserve test. *Human reproduction*. 1999; 15: 2822-2826
- Craft I, Gorgy A, Hill J. Will GnRH Antagonist Provide New Hope for Patient Considered ‘Difficult Responders’ to GnRH Agonist Protocols?. 1999;14(12):2959-2962.
- Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. *Cochrane Database Syst Rev* 2000, CD001299 Derman S, Seifer B, In vitro in the older patient. *Current women’s Health Report*. 2003;3: 375-83.
- Diedrich K, Diedrich C, Santos E, Zoll C, Al-Hasani S, Reissmann T, et al. Suppression of the Endogenous Luteinizing Hormone Surge by the Gonadotropin-Releasing Hormone Antagonist Cetrorelix During Ovarian Stimulation. *HumReprod* 9. 1994;788-791.
- Develioglu O.H, Cox Toner J.P, Oehninger S, Muasher S.J. The value of basal serum follicle stimulating hormone, luteinizing hormone and oestradiol concentrations following pituitary down-regulation in predicting ovarian response to stimulation with highly purified follicle stimulating hormone. The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School. *Hum Repro* .1998;14(5):1168–1174
- Dovey S, Sneeringer RM, Penzias AS: Clomiphene citrate and intrauterine insemination: analysis of more than 4100 cycles. *FertilSteril*. 2008;90(6): 2281-2286
- Eldar-Geva T, Calderon I, Maclachlan V, Healy D. *Endocrinology of IVF*. In: Trouson OA, Gardner DK, eds. *In Vitro fertilization*. Florida. CRC Press. 2000; 35-65
- Eldar-Geva T, Margalioth EJ, Chetrit AB. *Serum inhibin B levels measured early during FSH administration for IVF may be of value in predicting the number of oocyte to be retrieved in normal and low responders*. *Human Reproduction*. 2002;17(9):2331-2337.
- Fausser BC, Van Heusden AM: Manipulation of human ovarian function: physiology concepts and clinical consequences. *Endocr Rev*. 1997, 18: 71-106.
- Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, DeFatis CT: Low-dose human chorionic gonadotropin therapy can improve sensitivity to exogenous follicle-stimulating hormone in patients with secondary amenorrhea. *FertilSteril*. 1999;72:1118–1120.



- Gurgan I, Ayygul D. Recombinant luteinizing hormone in assisted reproductive technology. *Reviews in Gynaecological Practice*.2005;5(1):45-50.
- Huges J.N. Ovarian Stimulation for Assisted Montserrat Creus. In: Joana P, Francisco F, Ester V, Francisco C, Roser C, Juan A.V. et al. *Da 3 inhibin b and FSH and age as predictors of assisted reproduction tretment outcome*. 2000
- Homburg R, Howles CM: Low-dose FSH therapy for infertility anovulatory associated with polycystic ovary syndrome: rationale, results, reflections and refinements. *Hum Reprod Update* 1999, 5:493-499.
- Homburg R: Ovulation induction and controlled ovarian stimulation: a Practical Guide 2005, London and New York: Taylor & Francis.
- Imani B, Eijkemans MJ, Faessen GH, Bouchard P, Giudice LC, Fauser BC: Prediction of the individual follicle stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropicanovulatory infertility: an approach to increase safety and efficiency. *FertilSteril*2002, 77: 83-90.
- Ivo N. Roberto B. Mario M. Franca R. Antonio C. Gianfranco S. *low day 3 luteinizing hormone values are predictive of reduced response to ovarian stimulation*.1998
- Karimzadeh MA, Ghandi S. Age and basal FSH as a predictor of ART outcome. *Iranian Journal of Reproductive Medicine*. 2009;7(1): 19-22.
- Katsikis I. Karkanaki A. Misichronis G. Delkos D. Kandaraki EA. Panidis D. Phenotypic expression, body mass index and insulin resistance in relation to LH level in women with polycystic ovarian syndrome. *Eur J Obstet Gynecol*. 2011;156:181-85
- Kim Y.K. Samuel K.W. Victor Y.F. Nancy.A. Donald E.M. Michael R.S. *Utility of follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol and FSH:LH ratio in predicting reproductive age in normal women*.*Human Reproduction*. 1997;1:99-102
- Kojima R, Nakagawa K, Nakashima A. Elevated basal FSH levels, if it is under 15 IU/L, will not reflect poor ART outcomes. *J Assist Reprod Genet*.2008;25;73-77.
- Luke B. Brown MB. Missmer SA. Bukulmez O. Leach R. Stern JE. The effect of incresing obesity on the respon to and outcome of assisted reproductive technology. A national study. *Fertil steril*. 2011;96(4):820-25
- Ludwig M,Howles CM: Optimization of Ovarian Stimulation Protocols for Assisted Reproduction 2005, Hong Kong: CMP Medica.Macklon NS, Stouffer RL, Giudice LC, Fauser BC: The science behind 25 years of ovarian stimulation on in vitro fertilization. *Endocr Rev*2006, 27(2):170-207.
- Mukherjee T, Copperman AB, Lapinski R. An elevated day three follicle-stimulating hormone: luteinizing hormone ratio (FSH:LH) the presense of a normal day 3 FSH predict a poor response to controlled ovarian hyperstimulation. *Fertil steril*. 1996;5:588-593.
- Noci L, Biagiotti R, Maggi M. Low day 3 luteinizing hormonevalues are predictive of reduced response to ovarian stimulation. In: Fertility: Assesment and Treatment for people with Fertility Problem. Cilinal Guidelines.RCOG Press *Hum reprod*, 2004;13(53):531-534.
- Scott RT, Muaher SJ. Intercycle variability of day 3 follicle stimulating hormone levels and its effect on stimulation quality in vitro fertilization and embrio transfer. *Fertil Steril*, 1990;54: 297-302
- Sharara FI, Scott TR, Seifer BD. The detection of diminish ovarian reserve in infertile woman. *Am J Obstet Gynecol*. 1998;179:.804-12



Sharpe RM, Devroey P, Van Steirteghem AC. Endocrinology in luteal phase and implantation. *Br med Bull.* 1990;46:709-19

Smitz J, Devroey P, Van Steirteghem AC:Endocrinology in luteal phase and implantation. *Br Med Bull* 1990, 46:709–719.

Sperrof L, Glass RH, Kase NG. *Clinical Gynecologic endocrinologic and Infertility*, 6th rev.ed. USA: Lippicott Williams & Wilkins. 1999:1216-1234

Stouffer. Woodruff TK. Dahl KD. Hess DL. Mather JP. Molksness TA. Human recombinant activin a alters pituitary luteinizing hormone and follicle-stimulating hormone secretion follicular development, and steroidogenesis, during the menstrual cycle. *J Clin Endocr Metab.* 1993; 77:211-48

Tarlatzis B, Zepiridis L, Bontis J. Clinical Management of low ovarian response to stimulation for IVF : a systematic review. *Human Reproduction*,2003; 9(1) :61-75.

Tarlatzis BC, Fauser BC, Kolibiankis EM, Diedrich K, Devroy P. GnRH Antagonist in ovarian stimulation for IVF. *Human Reproduction Update.* 2006; 12(4):333-340.

Van Hooff MH, Alberda AT, Huisman GJ, Zeilmaker GH, Leerentveld RA:Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in lowresponders: a randomized study. *Hum Reprod.*1993, 8:369–373.

Verberg MF, Eijkmans MJ, Macklon NS. Prediction of Insufficient Ovarian Response Following mild Ovarian Stimulation for IVF. *Human Reproduction.* 2007;7:1919-24.

Wu HH, Wang NM, Cheng ML, Hsieh JN: A randomized comparison of ovulation induction and hormone profile between the aromatase inhibitor anastrozole and clomiphene citrate in women with infertility. *GynecolEndocrinol.*2007, 23(2):76-81